首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Simultaneous quantification of enalapril and enalaprilat in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.
【24h】

Simultaneous quantification of enalapril and enalaprilat in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.

机译:高效液相色谱-串联质谱法同时定量测定人血浆中的依那普利和依那普利特,并将其用于药代动力学研究。

获取原文
获取原文并翻译 | 示例
           

摘要

A rapid, selective and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed to simultaneously determine enalapril and enalaprilat in human plasma. With benazepril as internal standard, sample pretreatment involved in a one-step protein precipitation (PPT) with methanol of 0.2 ml plasma. Analysis was performed on an Ultimate XB-C(18) column (50 mm x 2.1 mm, i.d., 3 microm) with mobile phase consisting of methanol-water-formic acid (62:38:0.2, v/v/v). The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction-monitoring (MRM) mode via electrospray ionization (ESI) source. Each plasma sample was chromatographed within 2.5 min. The linear calibration curves for enalapril and enalaprilat were both obtained in the concentration range of 0.638-255 ng/ml (r(2) > or = 0.99) with the lower limit of quantification (LLOQ) of 0.638 ng/ml. The intra-day precision (R.S.D.) was below 7.2% and inter-day R.S.D. was less than 14%, while accuracy (relative error R.E.) was within +/-8.7 and +/-5.5%, determined from QC samples for enalapril and enalaprilat which corresponded to requirement of the guidance of FDA. The HPLC-MS/MS method herein described was fully validated and successfully applied to the pharmacokinetic study of enalapril maleate capsules in 20 healthy male volunteers after oral administration.
机译:建立了一种快速,选择性和灵敏的高效液相色谱-串联质谱(HPLC-MS / MS)方法,以同时测定人血浆中的依那普利和依那普利拉。以苯那普利为内标,样品预处理涉及用0.2 ml血浆甲醇进行一步蛋白沉淀(PPT)。在Ultimate XB-C(18)色谱柱(50 mm x 2.1 mm,i.d.,3微米)上进行分析,流动相由甲醇-水-甲酸(62:38:0.2,v / v / v)组成。通过多反应监测(MRM)模式通过电喷雾电离(ESI)源在三重四极杆串联质谱仪上进行检测。每个血浆样品在2.5分钟内进行色谱分离。依那普利和依那普利拉的线性校准曲线均在0.638-255 ng / ml的浓度范围内获得(r(2)>或= 0.99),定量下限(LLOQ)为0.638 ng / ml。日内精确度(R.S.D.)低于7.2%,日间R.S.D.依那普利和依那普利拉的质控样品测定的准确度(相对误差R.E.)在+/- 8.7和+/- 5.5%以内,与FDA指南的要求相对应。本文所述的HPLC-MS / MS方法已得到充分验证,并成功应用于口服后20名健康男性志愿者的依那普利马来酸酯胶囊的药代动力学研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号